BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity von Santag, Susann, Siegel, Franziska, Wengner, Antje M, Lange, Claudia, Bömer, Ulf, Eis, Knut, Pühler, Florian, Lienau, Philip, Bergemann, Linda, Michels, Martin, von Nussbaum, Franz, Mumberg, Dominik, Petersen, Kirstin

Volltext

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models von Politz, Oliver, Siegel, Franziska, Bärfacker, Lars, Bömer, Ulf, Hägebarth, Andrea, Scott, William J., Michels, Martin, Ince, Stuart, Neuhaus, Roland, Meyer, Kirstin, Fernández‐Montalván, Amaury Ernesto, Liu, Ningshu, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl

Volltext

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer von Lücking, Ulrich, Kosemund, Dirk, Böhnke, Niels, Lienau, Philip, Siemeister, Gerhard, Denner, Karsten, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Bömer, Ulf, Schäfer, Martina, Ince, Stuart, Mumberg, Dominik, Scholz, Arne, Izumi, Raquel, Hwang, Stuart, von Nussbaum, Franz

Volltext

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models von Wengner, Antje M, Siemeister, Gerhard, Lücking, Ulrich, Lefranc, Julien, Wortmann, Lars, Lienau, Philip, Bader, Benjamin, Bömer, Ulf, Moosmayer, Dieter, Eberspächer, Uwe, Golfier, Sven, Schatz, Christoph A, Baumgart, Simon J, Haendler, Bernard, Lejeune, Pascale, Schlicker, Andreas, von Nussbaum, Franz, Brands, Michael, Ziegelbauer, Karl, Mumberg, Dominik

Volltext

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer von Lücking, Ulrich, Scholz, Arne, Lienau, Philip, Siemeister, Gerhard, Kosemund, Dirk, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Meyer, Kirstin, Prelle, Katja, Denner, Karsten, Bömer, Ulf, Schäfer, Martina, Eis, Knut, Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl, Klebl, Bert, Choidas, Axel, Nussbaumer, Peter, Baumann, Matthias, Schultz‐Fademrecht, Carsten, Rühter, Gerd, Eickhoff, Jan, Brands, Michael

Volltext

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase von Schulze, Volker K, Klar, Ulrich, Kosemund, Dirk, Wengner, Antje M, Siemeister, Gerhard, Stöckigt, Detlef, Neuhaus, Roland, Lienau, Philip, Bader, Benjamin, Prechtl, Stefan, Holton, Simon J, Briem, Hans, Marquardt, Tobias, Schirok, Hartmut, Jautelat, Rolf, Bohlmann, Rolf, Nguyen, Duy, Fernández-Montalván, Amaury E, Bömer, Ulf, Eberspaecher, Uwe, Brüning, Michael, Döhr, Olaf, Raschke, Marian, Kreft, Bertolt, Mumberg, Dominik, Ziegelbauer, Karl, Brands, Michael, von Nussbaum, Franz, Koppitz, Marcus

Volltext

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monot... von Lücking, Ulrich, Wortmann, Lars, Wengner, Antje M, Lefranc, Julien, Lienau, Philip, Briem, Hans, Siemeister, Gerhard, Bömer, Ulf, Denner, Karsten, Schäfer, Martina, Koppitz, Marcus, Eis, Knut, Bartels, Florian, Bader, Benjamin, Bone, Wilhelm, Moosmayer, Dieter, Holton, Simon J, Eberspächer, Uwe, Grudzinska-Goebel, Joanna, Schatz, Christoph, Deeg, Gesa, Mumberg, Dominik, von Nussbaum, Franz

Volltext

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor von Lefranc, Julien, Schulze, Volker Klaus, Hillig, Roman Christian, Briem, Hans, Prinz, Florian, Mengel, Anne, Heinrich, Tobias, Balint, Jozsef, Rengachari, Srinivasan, Irlbacher, Horst, Stöckigt, Detlef, Bömer, Ulf, Bader, Benjamin, Gradl, Stefan Nikolaus, Nising, Carl Friedrich, von Nussbaum, Franz, Mumberg, Dominik, Panne, Daniel, Wengner, Antje Margret

Volltext

Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839 von Bothe, Ulrich, Günther, Judith, Nubbemeyer, Reinhard, Siebeneicher, Holger, Ring, Sven, Bömer, Ulf, Peters, Michaele, Rausch, Alexandra, Denner, Karsten, Himmel, Herbert, Sutter, Andreas, Terebesi, Ildiko, Lange, Martin, Wengner, Antje M., Guimond, Nicolas, Thaler, Tobias, Platzek, Johannes, Eberspächer, Uwe, Schäfer, Martina, Steuber, Holger, Zollner, Thomas M., Steinmeyer, Andreas, Schmidt, Nicole

Volltext

Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21 von Göricke, Fabian, Vu, Victoria, Smith, Leanna, Scheib, Ulrike, Böhm, Raphael, Akkilic, Namik, Wohlfahrt, Gerd, Weiske, Jörg, Bömer, Ulf, Brzezinka, Krzysztof, Lindner, Niels, Lienau, Philip, Gradl, Stefan, Beck, Hartmut, Brown, Peter J., Santhakumar, Vijayaratnam, Vedadi, Masoud, Barsyte-Lovejoy, Dalia, Arrowsmith, Cheryl H., Schmees, Norbert, Petersen, Kirstin

Volltext

A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy von Böhnke, Niels, Berger, Markus, Griebenow, Nils, Rottmann, Antje, Erkelenz, Michael, Hammer, Stefanie, Berndt, Sandra, Günther, Judith, Wengner, Antje M., Stelte-Ludwig, Beatrix, Mahlert, Christoph, Greven, Simone, Dietz, Lisa, Jörißen, Hannah, Barak, Naomi, Bömer, Ulf, Hillig, Roman C., Eberspaecher, Uwe, Weiske, Jörg, Giese, Anja, Mumberg, Dominik, Nising, Carl Friedrich, Weinmann, Hilmar, Sommer, Anette

Volltext

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models von Lemos, Clara, Schulze, Volker K., Baumgart, Simon J., Nevedomskaya, Ekaterina, Heinrich, Tobias, Lefranc, Julien, Bader, Benjamin, Christ, Clara D., Briem, Hans, Kuhnke, Lara P., Holton, Simon J., Bömer, Ulf, Lienau, Philip, von Nussbaum, Franz, Nising, Carl F., Bauser, Marcus, Hägebarth, Andrea, Mumberg, Dominik, Haendler, Bernard

Volltext

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies von Berger, Markus, Wortmann, Lars, Buchgraber, Philipp, Lücking, Ulrich, Zitzmann-Kolbe, Sabine, Wengner, Antje M, Bader, Benjamin, Bömer, Ulf, Briem, Hans, Eis, Knut, Rehwinkel, Hartmut, Bartels, Florian, Moosmayer, Dieter, Eberspächer, Uwe, Lienau, Philip, Hammer, Stefanie, Schatz, Christoph A, Wang, Qiuwen, Wang, Qi, Mumberg, Dominik, Nising, Carl F, Siemeister, Gerhard

Volltext

High-Throughput Screening for Kinase Inhibitors von von Ahsen, Oliver, Bömer, Ulf

Volltext

A Cost-Effective Solution to Reduce Dead Volume of a Standard Dispenser System by a Factor of 5 von Bergsdorf, Christian, Gewiese, Nadine, Stolz, Andreas, Mann, Rainer, Parczyk, Karsten, Bömer, Ulf

Volltext

Tom5 functionally links mitochondrial preprotein receptors to the general import pore von Pfanner, Nikolaus, Dietmeier, Klaus, Hönlinger, Angelika, Bömer, Ulf, Dekker, Peter J. T, Eckerskorn, Christoph, Lottspeich, Fritz, Kübrich, Michael

Volltext

Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor von Collin, Marie‐Pierre, Lobell, Mario, Hübsch, Walter, Brohm, Dirk, Schirok, Hartmut, Jautelat, Rolf, Lustig, Klemens, Bömer, Ulf, Vöhringer, Verena, Héroult, Mélanie, Grünewald, Sylvia, Hess‐Stumpp, Holger

Volltext

Abstract 5866: Discovery and profiling of a highly potent and selective ERK5 inhibitor: BAY-885 von Lemos, Clara, Nguyen, Duy, Wortmann, Lars, Bömer, Ulf, Holton, Simon, Lechner, Christian, Prechtl, Stefan, Sülzle, Detlev, Siegel, Franziska, Mumberg, Dominik, Bauser, Marcus, Hägebarth, Andrea

Volltext

Abstract 2907: Identification and optimization of a novel NAMPT inhibitor-based ADC payload class for cancer therapy von Böhnke, Niels, Berger, Markus, Griebenow, Nils, Giese, Anja, Günther, Judith, Sommer, Anette, Hammer, Stefanie, Berndt, Sandra, Wengner, Antje M., Beier, Rudolf, Stelte-Ludwig, Beatrix, Mahlert, Christoph, Greven, Simone, Dietz, Lisa, Joerissen, Hannah, Rottmann, Antje, Erkelenz, Michael, Barak, Naomi, Bömer, Ulf, Mumber, Dominik, Kreft, Bertolt, Linden, Lars, Nising, Carl Friedrich, Weinmann, Hilmar

Volltext

Abstract 4851: Second generation 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: development of BAY 1082439, a novel balanced PI3Ká / PI3Kâ inhibitor von Scott, William J., Liu, Ningshu, Hägebarth, Andreas, Möwes, Manfred, Mönning, Ursula, Bömer, Ulf, Mumberg, Dominik, von Nussbaum, Franz, Brands, Michael, Lafranc, Julien

Volltext